Table 1 Effects of bevacizumab on thoracic tumours in mice.

From: Fibrocyte-like cells mediate acquired resistance to anti-angiogenic therapy with bevacizumab

Y-MESO-14

Thoracic tumour

Pleural effusion

 

Incidence

Weight (mg)

Incidence

Volume (μl)

Control (n=4)

4/4

260 (210–330)

4/4

290 (200–700)

Bev 10 μg (n=5)

5/5

170 (100–250)*

4/5

50 (0–250)*

PC14PE6

Lung

Pleural effusion

 

Weight (mg)

Metastasis

Incidence

Volume (μl)

  

Incidence

Number

  

Control (n=7)

480 (320–880)

7/7

62 (25–87)

6/7

520 (0–750)

Bev 10 μg (n=7)

180 (170–200)†

6/7

17 (0–42)†

0/7

0

Bev 30 μg (n=7)

180 (150–250)†

7/7

29 (4–101)*

0/7

0

  1. MPM, malignant pleural mesothelioma; SCID, severe combined immunodeficient
  2. Y-MESO-14 (human MPM) cells were orthotopically injected to SCID mice, and PC14PE6 (human lung adenocarcinoma) cells were intravenously injected to nude mice. These mice were treated with bevacizumab (Bev) from day 7 after the tumour cell injection, and thoracic tumour, lung metastasis and pleural effusion were evaluated on day 28 (Y-MESO-14) or on day 35 (PC14PE6) after tumour cell injection. Values are the median (minimum–maximum).
  3. *Statistically significant difference compared with control group (P<0.05) by the Mann–Whitney-U-test.
  4. †Statistically significant difference compared with control group (P<0.01) by the Mann–Whitney-U-test.
Back to article page